Article

Methodological Challenges in Dutch HTA of Non-Oncological Orphan Drugs: A Retrospective Analysis and Price Comparison Using different Pricing Models

2025-05-20

Abstract excerpt

<title>Abstract</title> <p> <bold>Background</bold> Cost-effectiveness analyses can have limited informative value for pricing and reimbursement decisions for orphan drugs. In cases where cost-effectiveness cannot be reliably assessed or achieved, value-based pricing principles may not be applicable. As a result, alternative pricing models have been proposed. It remains unclear how these alternative approaches...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f8e45eb7-f4c0-559a-b054-801d01958640
DOI: 10.21203/rs.3.rs-6569819/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Methodological Challenges in Dutch HTA of Non-Oncological Orphan Drugs: A Retrospective Analysis and Price Comparison Using different Pricing ModelsDOI 10.21203/rs.3.rs-6569819/v1Read

Shining a light in the black box of orphan drug pricingSemantic proximity Read

Guiding the willingness to pay for repurposed tiratricol in the treatment of Allan-Herndon-Dudley syndrome using a cost-based-plus pricing frameworkSemantic proximity Read

Pricing Treatments Cost-Effectively When They Have Multiple Indications: Not Just a Simple Threshold AnalysisSemantic proximity Read

The costs and benefits of an early access scheme for oncology medicines in IrelandSemantic proximity Read

How the HTAR will contribute to a value-based decision making for medicinal products across the EUSemantic proximity Read

Quantifying the Dual Value and Governance Risks of Early Access Programs in Oncology: A Single-Centre Analysis and National Policy FrameworkSemantic proximity Read

Applying the Efficiency Frontier to Inform Value-Based Pricing for Gaucher Disease Therapies in BrazilSemantic proximity Read

Availability, Prices and Affordability of Nationally Negotiated Antidiabetic Drugs in China: A National SurveySemantic proximity Read

Access to Essential and Innovative Anti-cancer Medicines: A Longitudinal Study in Nanjing, ChinaSemantic proximity Read

Cost-effectiveness analysis of Sacituzumab tirumotecan versus Platinum-based chemotherapy for EGFR-TKI–Resistant, EGFR-Mutated Advanced NSCLC in ChinaSemantic proximity Read

Comparison Between Sotorasib with Docetaxel for the Treatment of Chinese Patients with Previously Treated NSCLC with KRASG12C Mutation: A Cost-Effectiveness Analysis to Inform Drug Pricing.Semantic proximity Read

Systematic Analysis and Quality Evaluation for Pharmacoeconomic Studies on Traditional Chinese MedicinesSemantic proximity Read